Adeno-Associated Viral Vectors Market Report 2026

The adeno-associated viral vectors market size has grown rapidly in recent years. It will grow from $3.17 billion in 2025 to $3.72 billion in 2026 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to early development of aav vector platforms, limited clinical adoption in rare diseases, initial regulatory guidelines for gene therapy, rising research in genetic disorder treatment, increasing funding for preclinical studies.

The adeno-associated viral vectors market size is expected to see rapid growth in the next few years. It will grow to $6.65 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to advancements in capsid engineering and vector design, growth in commercial gene therapy launches, increasing demand for personalized medicine, expansion of global clinical trials, rising collaborations between biotech and pharma companies. Major trends in the forecast period include expansion of aav-based gene therapies for rare genetic disorders, increasing investment in in vivo and ex vivo gene delivery methods, growing adoption of aav vectors in immunotherapy applications, rising focus on clinical and commercial-scale gene therapy programs, enhanced regulatory oversight and standardization of gene therapy products.

The increasing prevalence of genetic disorders is expected to drive the growth of the adeno-associated viral vectors market going forward. Genetic disorders are conditions that arise from abnormalities in an individual’s DNA, often resulting in physical or developmental impairments. Advancements in diagnostic technologies, increased awareness, higher maternal and paternal reproductive age, along with environmental influences and genetic drift, are contributing to the rising incidence of genetic disorders. Adeno-associated viral vectors are widely used in gene therapy to deliver corrective genes into target cells, enabling the potential treatment of conditions such as muscular dystrophy and cystic fibrosis. For instance, in February 2023, according to the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations responsible for international public health, congenital disorders account for an estimated 240,000 newborn deaths globally within the first 28 days of life each year, with an additional 170,000 deaths occurring among children aged one month to five years. Therefore, the increasing prevalence of genetic disorders is driving the adeno-associated viral vectors market.

Major companies operating in the adeno-associated viral vectors market are focusing on providing off-the-shelf availability of replication-capsid plasmids to gain a competitive advantage. Rep/Cap plasmids, which are essential for adeno-associated virus (AAV) vector production in gene therapy, are increasingly being supplied commercially to support molecular biology and therapeutic research. For instance, in January 2024, Charles River Laboratories International Inc., a US-based pharmaceutical company, launched an off-the-shelf replication-capsid plasmid range designed to streamline AAV-based gene therapy programs. This portfolio expansion complements the company’s existing lentiviral packaging and AAV helper plasmid offerings, reducing manufacturing efforts by up to 66%. These ready-to-use plasmids are produced in batches with comprehensive documentation, comply with CMC guidelines, and are provided with Certificates of Analysis (COA) to support IND and Clinical Trial Application (CTA) submissions.

In May 2024, Merck KGaA, a Germany-based company specializing in pharmaceuticals, biotechnology, and chemical materials, acquired Mirus Bio LLC for $600 million. Through this acquisition, Merck KGaA aims to strengthen its life sciences capabilities by incorporating Mirus Bio LLC’s advanced technologies for RNA-based research and therapeutic applications, enhancing its position in the expanding genetic engineering and biotechnology market and reinforcing its commitment to innovative biopharmaceutical development. Mirus Bio LLC is a US-based company that provides adeno-associated viral (AAV) vectors and gene delivery technologies.

Major companies operating in the adeno-associated viral vectors market are Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma B.V., Spark Therapeutics Inc., Akouos Inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc., MeiraGTx Holdings plc, GenSight Biologics S.A., Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics.

North America was the largest region in the adeno-associated viral vectors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adeno-associated viral vectors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adeno-associated viral vectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the adeno-associated viral vectors market by increasing costs for imported viral vector materials, lab equipment, and reagents used in gene therapy development. Segments such as gene augmentation, immunotherapy, and in vivo delivery methods are most affected, with north america, europe, and asia-pacific regions facing higher import duties. While tariffs have increased production and operational costs, they have also encouraged local manufacturing initiatives, boosting domestic capabilities and reducing dependency on imports over time.

The adeno-associated viral vectors market research report is one of a series of new reports that provides adeno-associated viral vectors market statistics, including adeno-associated viral vectors industry global market size, regional shares, competitors with a adeno-associated viral vectors market share, detailed adeno-associated viral vectors market segments, market trends and opportunities, and any further data you may need to thrive in the adeno-associated viral vectors industry. This adeno-associated viral vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Adeno-associated viral vectors (AAVs) are small, non-pathogenic viruses widely used in gene therapy. They are engineered to deliver therapeutic genes into target cells, offering potential treatments for genetic disorders, cancers, and other diseases. Their favorable safety profile and ability to efficiently infect both dividing and non-dividing cells make AAVs valuable tools in biomedical research and clinical applications.

The main types of adeno-associated viral vector therapies include gene augmentation, immunotherapy, and others. Gene augmentation involves introducing a functional gene to replace or supplement a defective or missing gene in a patient’s cells. Gene delivery methods include ex vivo and in vivo approaches, which are applied to therapeutic areas such as genetic disorders, hematological disorders, infectious diseases, metabolic disorders, ophthalmic disorders, muscle disorders, neurological disorders, and others. The scale of operation ranges from preclinical to clinical and commercial stages and is applied in gene therapy, cell therapy, and vaccine development.

The adeno-associated viral vectors market consists of sales of recombinant adeno-associated viral vectors (AAV), serotype-specific adeno-associated viral vectors (AAV), and custom adeno-associated viral vectors (AAV). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.